Employees at The Jackson Laboratory (JAX) rank Edison Liu in the Top 20% of CEOs in Bangor, ME. Comparatively, employees at Taconic Biosciences rank Bob Rosenthal in the Bottom 5% of CEOs in Pittsfield, MA. Employees rate their CEO differently based on the frequency of interaction, ability to affect company culture, and drive measurable results.

Edison Liu

CEO of The Jackson Laboratory (JAX)

BIO: Founded in 1929, The Jackson Laboratory is a world leader in complex genetics and genomics research. As President, I am responsible for the operations, recruitment, and business strategy of the institution, having over 2,200 full time employees and 75+ Principal Investigators on four campuses (ME, CA, CT). As CEO, I serve as Director of the National Cancer Institute designated JAX Cancer Center (established in 1983) and set in place the scientific direction of JAX. My scientific research focuses on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes, and deciphering -- on a genomic scale -- the dynamics of gene regulation that modulate cancer biology.

Bob Rosenthal

CEO of Taconic Biosciences

BIO: Dr. Robert J. Rosenthal has more than 30 years of experience relating to companies involved in the development of diagnostics, therapeutics, medical devices, and life sciences tools. He currently serves on the Safeguard Scientifics, Inc. Board of Directors, where he is Chairman of the Capital Management Committee and a member of the Audit Committee and Compensation Committee. Prior to Taconic, Bob’s recent executive leadership roles include; Chairman of the Board and Chief Executive Officer of IMI Intelligent Medical Implants AG, a medical technology company that developed a retinal implant system for degenerative disorders; and as President, Chief Executive Officer and a Director of Magellan Biosciences, Inc., a provider of life sciences research tools, which he founded. His specific experiences include; strategic planning and positioning, corporate and product development, operations management, capital markets transactions, debt and equity financing, fund-raising, merger and acquisition transactions, corporate finance as well as public and private company board experience. Bob holds a BS degree from the University of Maryland, an MS from State University of New York, a PhD from Emory University and an Executive MBA from Stanford University. He completed a post-doctoral fellowship at Universität Würzburg, Germany, as a guest scientist of the Alexander von Humboldt Foundation, followed by an additional post-doctoral fellowship at UCLA.